This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATNX Athenex (ATNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Athenex Stock (NASDAQ:ATNX) 30 days 90 days 365 days Advanced Chart Get Athenex alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.20▼$1.5252-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. Read More Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNX Stock News HeadlinesBiopharmaceutical company expands in time to take on Athenex businessDecember 26, 2023 | bizjournals.comOnly 2 local CEOs score highly with both employees and investorsNovember 22, 2023 | bizjournals.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 8 at 2:00 AM | Weiss Ratings (Ad)Athenex assets sold in bankruptcy auction; top executives dismissedJuly 31, 2023 | bizjournals.comAthenex (NASDAQ: ATNX)June 11, 2023 | fool.comBuffalo's drug development scene expected to continue in Athenex's wakeJune 1, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 17, 2023 | bizjournals.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceMay 16, 2023 | uk.finance.yahoo.comSee More Headlines ATNX Stock Analysis - Frequently Asked Questions How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative net margin of 86.31% and a negative trailing twelve-month return on equity of 727.79%. When did Athenex IPO? Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F). Company Calendar Last Earnings11/04/2021Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNX CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year Founded2003Profitability EPS (Trailing Twelve Months)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.43 million Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ATNX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.